These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15252266)

  • 21. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.
    Spathis AD; Asvos X; Ziavra D; Karampelas T; Topouzis S; Cournia Z; Qing X; Alexakos P; Smits LM; Dalla C; Rideout HJ; Schwamborn JC; Tamvakopoulos C; Fokas D; Vassilatis DK
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3999-4004. PubMed ID: 28348207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered Expression of D1 and D2 Dopamine Receptors in Vagal Neurons Innervating the Gastric Muscularis Externa in a Parkinson's Disease Rat Model.
    Wang ZY; Lian H; Zhou L; Zhang YM; Cai QQ; Zheng LF; Zhu JX
    J Parkinsons Dis; 2016 May; 6(2):317-23. PubMed ID: 27164043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP10-Dopamine Conjugate as a Potential Therapeutic Agent in the Treatment of Parkinson's Disease.
    Rusiecka I; Ruczyński J; Kozłowska A; Backtrog E; Mucha P; Kocić I; Rekowski P
    Bioconjug Chem; 2019 Mar; 30(3):760-774. PubMed ID: 30653302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
    Yabuki Y; Ohizumi Y; Yokosuka A; Mimaki Y; Fukunaga K
    Neuroscience; 2014 Feb; 259():126-41. PubMed ID: 24316474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Designing prodrugs for the treatment of Parkinson's disease.
    Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
    Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel para-phenyl substituted diindolylmethanes protect against MPTP neurotoxicity and suppress glial activation in a mouse model of Parkinson's disease.
    De Miranda BR; Popichak KA; Hammond SL; Miller JA; Safe S; Tjalkens RB
    Toxicol Sci; 2015 Feb; 143(2):360-73. PubMed ID: 25406165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenic Upregulation of Glial Lipocalin-2 in the Parkinsonian Dopaminergic System.
    Kim BW; Jeong KH; Kim JH; Jin M; Kim JH; Lee MG; Choi DK; Won SY; McLean C; Jeon MT; Lee HW; Kim SR; Suk K
    J Neurosci; 2016 May; 36(20):5608-22. PubMed ID: 27194339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
    Delfino MA; Stefano AV; Ferrario JE; Taravini IR; Murer MG; Gershanik OS
    Behav Brain Res; 2004 Jul; 152(2):297-306. PubMed ID: 15196797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease.
    Zhang Z; Li X; Xie WJ; Tuo H; Hintermann S; Jankovic J; Le W
    CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):768-73. PubMed ID: 22483304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DJ-1-dependent protective activity of DJ-1-binding compound no. 23 against neuronal cell death in MPTP-treated mouse model of Parkinson's disease.
    Takahashi-Niki K; Inafune A; Michitani N; Hatakeyama Y; Suzuki K; Sasaki M; Kitamura Y; Niki T; Iguchi-Ariga SM; Ariga H
    J Pharmacol Sci; 2015 Mar; 127(3):305-10. PubMed ID: 25837927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry.
    Depboylu C; Maurer L; Matusch A; Hermanns G; Windolph A; Béhé M; Oertel WH; Höglinger GU
    Neuroimage; 2013 Oct; 79():191-200. PubMed ID: 23631981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
    Kato H; Araki T; Imai Y; Takahashi A; Itoyama Y
    J Neurol Sci; 2003 Apr; 208(1-2):9-15. PubMed ID: 12639719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression.
    Campbell JC; Jeyamohan SB; De La Cruz P; Chen N; Shin D; Pilitsis JG
    Behav Brain Res; 2014 Dec; 275():114-9. PubMed ID: 25205367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Shimizu M; Tanaka K; Ogawa N
    Neurol Res; 2005 Jul; 27(5):533-9. PubMed ID: 15978181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.